Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
PaperCitations, authors & open-access status
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 263 citations, 2025 year and green oa status.
263
Citations
2025
Year
green
OA Status